Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Deferred Tax (2017 - 2025)

Corcept Therapeutics' Long-Term Deferred Tax history spans 9 years, with the latest figure at $153.0 million for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 20.66% year-over-year to $153.0 million; the TTM value through Sep 2025 reached $153.0 million, up 20.66%, while the annual FY2024 figure was $130.9 million, 44.49% up from the prior year.
  • Long-Term Deferred Tax for Q3 2025 was $153.0 million at Corcept Therapeutics, down from $162.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $162.2 million in Q2 2025 and bottomed at $27.5 million in Q4 2021.
  • The 5-year median for Long-Term Deferred Tax is $78.2 million (2023), against an average of $83.4 million.
  • The largest annual shift saw Long-Term Deferred Tax decreased 13.13% in 2021 before it skyrocketed 123.88% in 2022.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $27.5 million in 2021, then surged by 123.88% to $61.5 million in 2022, then soared by 47.41% to $90.6 million in 2023, then skyrocketed by 44.49% to $130.9 million in 2024, then grew by 16.87% to $153.0 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Long-Term Deferred Tax are $153.0 million (Q3 2025), $162.2 million (Q2 2025), and $144.4 million (Q1 2025).